Market Assessment, Chronic Heart Failure Treatment Algorithms: Claims Data Analysis US 2017 Report

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, oral beta blocker, and oral diuretic. Second- or third-line treatments is often needed to better manage the disease. Physicians have numerous drug classes to choose from, most of which have many drug options. The CHF market is heavily genericized, as such physicians are less constrained by pricing pressures. The CHF Treatment Algorithm offers insight into prescribing patterns following the increase in generic drug availability. That said, there are a few branded agents that jostle for patient share in this crowded sector. Small patient shares for such a prevalent indication can translate into significant commercial positions.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Chronic Heart Failure | Treatment Algorithms: Claims Data Analysis | US | 2017

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

Breast Cancer – Unmet Need – Detailed, Expanded Analysis: Advanced Or Metastatic HER2-Positive Breast Cancer (US/EU)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)

Male Hypogonadism – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Reduced Ejection Fraction (US)